Viewing Study NCT03302728


Ignite Creation Date: 2025-12-26 @ 11:14 AM
Ignite Modification Date: 2025-12-29 @ 5:54 PM
Study NCT ID: NCT03302728
Status: COMPLETED
Last Update Posted: 2022-05-19
First Post: 2017-10-01
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Sponsor: Peter MacCallum Cancer Centre, Australia
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module